Try our beta test site
Trial record 2 of 22 for:    novocure

Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by NovoCure Ltd.
Information provided by (Responsible Party):
NovoCure Ltd. Identifier:
First received: July 8, 2016
Last updated: March 14, 2017
Last verified: March 2017
The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1-10 brain metastases, treated with NovoTTF-100M compared to supportive treatment alone. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

Condition Intervention Phase
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Device: NovoTTF-100M device
Other: Best Standard of Care
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) (150kHz) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC)

Resource links provided by NLM:

Further study details as provided by NovoCure Ltd.:

Primary Outcome Measures:
  • Time to first cerebral progression [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • Time to neurocognitive failure [ Time Frame: 3 years ]
    Measured by cognitive decline on a battery of tests: Hopkins Verbal Learning Test (HVLT-R) free recall, delayed recall, and delayed recognition; Controlled Oral Word Association Test (COWAT); and Trail Making Tests (TMT) Parts A and B

  • Overall survival [ Time Frame: 3 years ]
  • Radiological response in the brain [ Time Frame: 3 years ]
  • Time to second cerebral progression [ Time Frame: 3 years ]
  • Time to first and second cerebral progression evaluated in two cohorts, 1-4 brain metastases and 5-10 brain metastases. [ Time Frame: 3 years ]
  • Rate of cerebral progression at 2, 4, 6, 8, 10, 12 months [ Time Frame: 3 years ]
  • Intracranial progression free survival [ Time Frame: 3 years ]
  • Time to distant progression in the supratentorial region [ Time Frame: 3 years ]
  • Rate of decline in cognitive function at 2, 4, 6, 8, 10, 12 months [ Time Frame: 3 years ]
    Measured by HVLT-R free recall, delayed recall, and delayed recognition; COWAT; and TMT Parts A and B

  • Neurocognitive failure-free survival [ Time Frame: 3 years ]
    Defined from the date of first SRS treatment to neurocognitive failure (as measured by HVLT-R free recall, delayed recall, and delayed recognition; COWAT; and TMT Parts A and B) or death (whichever occurs first), censored at the last neurocognitive assessment on which the patient was reported alive without neurocognitive failure

  • Quality of Life using the EORTC QLQ C30 with BN20 addendum [ Time Frame: 3 years ]
  • Toxicity during NovoTTF-100M treatment based on incidence and severity of treatment emergent adverse events as evaluated using the CTCAE version 4.0 [ Time Frame: 3 years ]

Estimated Enrollment: 270
Study Start Date: July 2016
Estimated Study Completion Date: July 2019
Estimated Primary Completion Date: July 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NovoTTF-100M device
Patients undergo SRS followed by continuous TTFields treatment using the NovoTTF-100M device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
Device: NovoTTF-100M device
Active Comparator: Best Standard of Care
Patients will undergo SRS alone and be treated with the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain.
Other: Best Standard of Care

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. 18 years of age and older
  2. Life expectancy of ≥ 3 months
  3. New diagnosis of brain metastases from a histologically or cytologically confirmed primary or metastatic NSCLC tumor within 5 years of registration on the study. If the original histological proof of malignancy is greater than 5 years, then pathological confirmation is required (i.e.: from extra-cranial or intracranial disease).
  4. Karnofsky performance status (KPS) ≥ 70
  5. Graded Prognostic Assessment (GPA) score ≥ 2.0
  6. 1 inoperable brain metastasis or 2- 10 brain lesions per screening MRI, confirmed by contrast enhanced MRI amenable to SRS according to the following criteria:

    1. largest tumor volume < 10 cc
    2. longest tumor diameter < 3 cm
    3. Cumulative volume of all tumors ≤ 15 cc
  7. At least one measurable lesion per RANO-BM (Response Assessment in Neuro-Oncology Brain Metastases) Criteria for brain metastasis
  8. Patients must be receiving optimal therapy for their extracranial disease according to local practice at each center. Patients may continue on systemic therapy while receiving TTFields.
  9. Able to operate the NovoTTF-100M device independently or with the help of a caregiver
  10. Clinical trials prior to enrollment are allowed, as long as no brain directed therapy was included (current treatment trials are exclusionary)

Exclusion Criteria:

  1. Patients who are known to have somatic tumor mutations in the following genes, for which targeted agents are available that directly affect the treatment of brain metastasis: Anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), ROS-1 proto-oncogene, and proto-oncogene B-RAF
  2. Patients who have a single, operable brain metastasis
  3. Patients with significant edema leading to risk of brain herniation
  4. Patients with midline shift > 10mm
  5. Patients with intractable seizures
  6. Infratentorial metastases
  7. Leptomeningeal metastases
  8. Recurrent brain metastases or brain metastases previously treated with surgery and/or radiosurgery and/or brain radiotherapy
  9. Prior surgical resection or WBRT for newly diagnosed brain metastases (needle biopsy for diagnosis establishment is allowed)
  10. Severe comorbidities:

    1. Clinically-significant inadequate hematological, hepatic and renal function, defined as: Neutrophil count < 1.5 x 10 9/L and platelet count < 100 x 10^9/L; bilirubin > 1.5 x upper limit of normal (ULN); aspartate transaminase (AST) and/or alanine aminotransferase (ALT) > 2.5 x ULN or > 5 x ULN if patient has documented liver metastases; and serum creatinine > 1.5 x ULN
    2. History of significant cardiovascular disease unless the disease is well controlled. Significant cardiac disease includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary activity results in fatigue, palpitation or dyspnea).
    3. History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the trial.
    4. History of cerebrovascular accident (CVA) within 6 months prior to randomization or that is not stable
    5. Active infection or serious underlying medical condition that would impair the ability of the patient to received protocol therapy
    6. History of any psychiatric condition that might impair patient's ability to understand or comply with the requirements of the study or to provide consent
  11. Implantable electronic medical devices in the brain
  12. Known allergies to medical adhesives or hydrogel
  13. Currently pregnant or breastfeeding
  14. Concurrent brain directed therapy (beyond SRS and NovoTTF-100M as per protocol)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02831959

Contact: Ghazala Kabani

  Hide Study Locations
United States, Alabama
University of Alabama at Birmingham Comprehensive Cancer Center Not yet recruiting
Birmingham, Alabama, United States, 35294
Contact: Melissa Deakle   
Contact: Anna Messer   
Principal Investigator: John Fiveash, MD         
United States, Arizona
University of Arizona Cancer Center Not yet recruiting
Tucson, Arizona, United States, 85170
Contact: Ruth Canamar    520-626-6515   
Principal Investigator: Hani Babiker, MD         
United States, California
USC Norris Comprehensive Cancer Center Not yet recruiting
Los Angeles, California, United States, 90033
Contact: Sandy Leong    323-442-7532   
Principal Investigator: Thomas Chen, MD         
Cedars-Sinai Medical Center Not yet recruiting
Los Angeles, California, United States, 90048
Contact: Felix Luz    310-423-5379   
Principal Investigator: Jethro Hu, MD         
Chao Family Comprehensive Cancer Center Recruiting
Orange, California, United States, 92868
Contact: Jinah Chung    877-827-8839   
Principal Investigator: Jose Carrillo, MD         
The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange Recruiting
Orange, California, United States, 92868
Contact: Martha French    714-734-6200 ext 40838   
Principal Investigator: Venita Williams, MD         
United States, Connecticut
Associated Neurologists of Southern CT Recruiting
Fairfield, Connecticut, United States, 06824
Contact: Micah Sy    203-333-1151   
Principal Investigator: Nicholas Blondin, MD         
United States, Florida
University of Florida Recruiting
Gainesville, Florida, United States, 32611
Contact: Sarah Andrews, RN    352-273-7981   
Principal Investigator: David Tran, MD         
Miami Cancer Institute Recruiting
Miami, Florida, United States, 33176
Contact: Jessica Gonzalez-Salas    786-527-8112   
Principal Investigator: Minesh Mehta, MD         
United States, Georgia
Piedmont Brain Tumor Center Recruiting
Atlanta, Georgia, United States, 30309
Contact: Shirley Elkins    404-605-2050   
Principal Investigator: Adam Nowlan, MD         
United States, Illinois
Northwestern University Not yet recruiting
Chicago, Illinois, United States, 60611
Contact: Ann Mendelke    312-695-1383   
Principal Investigator: Priya Kumthekar, MD         
The University of Chicago Not yet recruiting
Chicago, Illinois, United States, 60637
Contact: Gabe Pugel    773-702-5928   
Principal Investigator: Rimas Lukas, MD         
CDH-Delnor Health System Recruiting
Warrenville, Illinois, United States, 60555
Contact: Donald Smith, MS, CCRC    603-352-5360    Donald.Smith@CadenceHealth.Org   
Principal Investigator: Vinai Gondi, MD         
United States, Kentucky
St. Elizabeth Healthcare Cancer Care Center Recruiting
Edgewood, Kentucky, United States, 41017
Contact: Darla Hehman, RN    859-301-5473   
Principal Investigator: Robert Albright, MD         
University of Louisville Recruiting
Louisville, Kentucky, United States, 40202
Contact: Erika Hargis    502-217-5244   
Principal Investigator: Eric Burton, MD         
United States, Louisiana
Ochsner Clinic Foundation Not yet recruiting
New Orleans, Louisiana, United States, 70121
Contact: Lanie Sansing    504-842-8769   
Principal Investigator: Marcus Ware, MD, PhD         
United States, Massachusetts
Tufts Medical Center Recruiting
Boston, Massachusetts, United States, 02111
Contact: Leanne Ianniello    617-636-2883   
Principal Investigator: Suriya Jeyapalan, MD         
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Christina Ng    617-667-1832   
Principal Investigator: Eric Wong, MD         
United States, Michigan
21st Century Oncology Recruiting
Troy, Michigan, United States, 48098
Contact: Paulette Palazzolo    248-672-7745   
Principal Investigator: Vito John Antonucci, MD         
United States, Minnesota
John Nasseff Neuroscience Institute ANW Brain Tumor Center Recruiting
Minneapolis, Minnesota, United States, 55407
Contact: Meghan Hultman    612-863-3308   
Principal Investigator: John Trusheim, MD         
Masonic Cancer Clinic Recruiting
Minneapolis, Minnesota, United States, 55454
Contact: Kim Sieckowski    612-626-4495   
Contact: Almarie Coleman    (612)-624-5949   
Principal Investigator: Emil Lou, MD         
Mayo Clinic Not yet recruiting
Rochester, Minnesota, United States, 55905
Contact: Justin Buroker    507-293-0624   
Principal Investigator: Daniel Ma, MD         
United States, New York
Weil Cornell Medical College/New York Presbyterian Hospital Recruiting
New York, New York, United States, 10021
Contact: Amanda De Laurentiis    646-962-9349   
Principal Investigator: Ronald Scheff, MD         
Mount Sinai Hospital Not yet recruiting
New York, New York, United States, 10029
Principal Investigator: Isabelle Germano, MD         
Columbia University Medical Center Neurological Institute of New York Not yet recruiting
New York, New York, United States, 10032
Contact: David Cieremans    212-304-5570   
Principal Investigator: Teri Kreisl, MD         
United States, North Carolina
East Carolina University Recruiting
Greenville, North Carolina, United States, 27834
Contact: Renee Coghill    252-744-5723   
Contact: Amanda Wetherington    252-744-5687   
Principal Investigator: Clinton Leinweber, MD         
Wake Forest Health Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Shirley Coe    336-713-6505   
Contact: Jennifer Black    336-716-9342   
Principal Investigator: Michael Chan, MD         
United States, Pennsylvania
Geisinger Medical Center Not yet recruiting
Danville, Pennsylvania, United States, 17822
Contact: Chelsie Derr    570-271-6590   
Principal Investigator: Scott Turner, MD         
Hospital of the University of Pennsylvania Not yet recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Suzanna Frangos    215-615-4186   
Principal Investigator: Steven Brem, MD         
United States, Rhode Island
Rhode Island Hospital Not yet recruiting
Providence, Rhode Island, United States, 02903
Principal Investigator: Steven Toms, MD         
United States, Tennessee
West Cancer Center Recruiting
Germantown, Tennessee, United States, 38138
Contact: Rachel Adams, CCRP    910-683-0055 ext 63005   
Principal Investigator: Matthew Ballo, MD         
United States, Texas
The University of Texas M.D. Anderson Cancer Center Not yet recruiting
Houston, Texas, United States, 77030
Contact: Victoria Cox    713-792-4928   
Principal Investigator: Jing Li, MD         
Joe Arrington Cancer Research and Treatment Center Recruiting
Lubbock, Texas, United States, 79410
Contact: Sonia Salas    806-725-8068   
Principal Investigator: Paul Anderson, MD         
Baylor Scott & White Health Recruiting
Temple, Texas, United States, 76505
Contact: Dedra Preece, CRC    254-771-4826   
Principal Investigator: Ekokobe Fonkem, MD         
United States, Virginia
University of VA Health Sciences Center Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Joe Farrar, BS    434-982-6455   
Principal Investigator: Jason Sheehan, MD         
Sentara Health Recruiting
Norfolk, Virginia, United States, 23507
Contact: Rebecca M Lee    757-388-4393   
Principal Investigator: Wylie Zhu, MD         
United States, Wisconsin
Froedtert and Medical College of Wisconsin Cancer Center Not yet recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Matt Lasowski    414-805-8375   
Principal Investigator: Jennifer Connelly, MD         
Canada, Manitoba
Cancercare Manitoba Not yet recruiting
Winnipeg, Manitoba, Canada, R3E 0V9
Principal Investigator: Saranya Kakumanu, MD         
Canada, Ontario
London Health Sciences Centre Not yet recruiting
London, Ontario, Canada, N6A 5A5
Contact: Al Gratton    579-685-8618      
Principal Investigator: Brian Yaremko, MD         
Canada, Quebec
Notre-Dame Hospital CHUM Not yet recruiting
Montreal, Quebec, Canada, H2L 4M1
Principal Investigator: David Roberge, MD         
Jewish General Hospital Not yet recruiting
Montreal, Quebec, Canada, H3T 1E2
Contact: Thierry Muanza    (514)-340-8288   
Principal Investigator: Thierry Muanza, MD         
Hôpital Maisonneuve-Rosemont Not yet recruiting
Montréal, Quebec, Canada, H1T-2M4
Contact: Linda Roy-Huneault    (514)-252-3400 ext 3227   
Principal Investigator: Pierre Chabot, MD         
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS) Not yet recruiting
Sherbrooke, Quebec, Canada, J1H 5N4
Contact: Anick Champous    (819)-346-1110 ext 12811   
Principal Investigator: David Mathieu, MD         
Sponsors and Collaborators
NovoCure Ltd.
Principal Investigator: Minesh Mehta, MD Miami Cancer Institute, Miami FL USA
Principal Investigator: Paul Brown, MD MD Anderson Cancer Center, Houston TX USA
Principal Investigator: Vinai Gondi Northwestern Medicine Cancer Center, Warenville IL USA
  More Information

Brozova H, Lucas A, Salmaggi A, Vymazal J. COMET: A phase II randomized study of TTFields versus supportive care in non-small cell lung cancer patients with 1-5 brain metastases - initial safety results. Neuro Oncol. 2015 Nov; 17 (suppl 5): v46. doi:10.1093/neuonc/nov208.6

Responsible Party: NovoCure Ltd. Identifier: NCT02831959     History of Changes
Other Study ID Numbers: EF-25
Study First Received: July 8, 2016
Last Updated: March 14, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by NovoCure Ltd.:
Non-Small Cell Lung Cancer
Brain metastases
Minimal toxicity
Tumor Treating Fields
Stereotactic radiosurgery

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Neoplasms, Second Primary
Brain Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Neoplastic Processes
Pathologic Processes
Central Nervous System Neoplasms
Nervous System Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases processed this record on March 22, 2017